Apixaban: an oral direct factor-xa inhibitor.

@article{Jimnez2012ApixabanAO,
  title={Apixaban: an oral direct factor-xa inhibitor.},
  author={David Jim{\'e}nez and Roger D. Yusen and Eduardo Ramacciotti},
  journal={Advances in therapy},
  year={2012},
  volume={29 3},
  pages={187-201}
}
Apixaban is a highly selective, reversible, direct factor Xa inhibitor that inhibits both free factor Xa and prothrombinase activity, and clot-bound factor Xa activity. A predictable pharmacokinetic profile, multiple pathways of elimination, an improved bleeding profile relative to warfarin with a lack of other significant adverse events, and no need for routine anticoagulation monitoring make apixaban appealing. Apixaban is currently approved for venous thromboembolism (VTE) prophylaxis in… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 42 extracted citations

Similar Papers

Loading similar papers…